NZ612525B2 - Bridged piperidine derivatives - Google Patents

Bridged piperidine derivatives Download PDF

Info

Publication number
NZ612525B2
NZ612525B2 NZ612525A NZ61252512A NZ612525B2 NZ 612525 B2 NZ612525 B2 NZ 612525B2 NZ 612525 A NZ612525 A NZ 612525A NZ 61252512 A NZ61252512 A NZ 61252512A NZ 612525 B2 NZ612525 B2 NZ 612525B2
Authority
NZ
New Zealand
Prior art keywords
methyl
rac
triazolo
bicyclo
amine
Prior art date
Application number
NZ612525A
Other versions
NZ612525A (en
Inventor
Karlheinz Baumann
Luke Green
Anja Limberg
Thomas Luebbers
Andrew Thomas
Original Assignee
F Hoffmannla Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmannla Roche Ag filed Critical F Hoffmannla Roche Ag
Priority claimed from PCT/EP2012/053301 external-priority patent/WO2012116965A1/en
Publication of NZ612525A publication Critical patent/NZ612525A/en
Publication of NZ612525B2 publication Critical patent/NZ612525B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Provided are bridged piperidine derivative compounds of general formula (I), where the variables are as defined in the specification. Examples of the compounds include [(rac)-3-exo-8-(2-Chloropyridin-4-yl)-8-aza-bicyclo [3.2.1 ] oct-3-yl]-[8-(3,4-difluorophenyl)-6-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine and 2-{6-(4-Chloro-benzyl)-2-[(rac)-3-endo-8-(3-methyl-[1,2,4]thiadiazol-5-yl)-8-azabicyclo[3.2.1] oct-3-ylamino]-pyrimidin-4-yl}-propan-2-ol. The compounds are modulators of amyloid beta and may be useful in the treatment or prevention of Alzheimer’s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome. Further provided are tablet and capsule formulations comprising the compounds. in-2-yl]-amine and 2-{6-(4-Chloro-benzyl)-2-[(rac)-3-endo-8-(3-methyl-[1,2,4]thiadiazol-5-yl)-8-azabicyclo[3.2.1] oct-3-ylamino]-pyrimidin-4-yl}-propan-2-ol. The compounds are modulators of amyloid beta and may be useful in the treatment or prevention of Alzheimer’s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome. Further provided are tablet and capsule formulations comprising the compounds.

Description

Bridged piperidine derivatives The present invention relates to compounds of formula hetaryl II (R ) (R ) hetaryl I hetaryl I is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N; hetaryl II is a six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N, or is a two membered ring system containing 1 to 4 heteroatoms selected from S, or N, wherein at least one ring is aromatic in nature; R is lower alkyl, lower alkoxy, lower alkyl substituted by halogen or halogen; R is lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, cycloalkyl substituted by lower alkyl or lower alkyl substituted by halogen, or is lower alkyl substituted by hydroxy, furyl, O-benzyl, or –(CH ) -phenyl, optionally substituted by halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkyl or by cyano; R is hydrogen or lower alkyl; Y is –(CH ) -, -CH OCH -, -CH O-, CH S-, -CH SCH - and is bonded to two of the 2 n 2 2 2 2 2 2 ring carbon atoms, bonding being to either the ring carbon atoms a and b or the ring carbon atoms c and d; p is 0 or 1; m is 0, 1 or 2; if m is 2 then R may be the same or different; POP / 02.01.2012 n is 2 or 3; o is 0, 1 or 2, if o is 2, then R may be the same or different; or to pharmaceutically active acid addition salts thereof.
Now it has been found that the present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer’s disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
Alzheimer’s disease (AD) is the most common cause of dementia in later life.
Pathologically, AD is characterized by the deposition of amyloid in extracellular plaques and intracellular neurofibrillary tangles in the brain. The amyloid plaques are mainly composed of amyloid peptides (Aβ peptides) which originate from the β-Amyloid Precursor Protein (APP) by a series of proteolytic cleavage steps. Several forms of APP have been identified of which the most abundant are proteins of 695, 751 and 770 amino acids length. They all arise from a single gene through differential splicing. The Aβ peptides are derived from the same domain of the APP.
Aβ peptides are produced from APP through the sequential action of two proteolytic enzymes termed β- and γ-secretase. β-Secretase cleaves first in the extracellular domain of APP just outside of the trans-membrane domain (TM) to produce a C-terminal fragment of APP containing the TM- and cytoplasmatic domain (CTFβ). CTFβ is the substrate for γ-secretase which cleaves at several adjacent positions within the TM to produce the Aβ peptides and the cytoplasmic fragment. Various proteolytic cleavages mediated by γ-secretase result in Aβ peptides of different chain length, e.g. Aβ38, Aβ40 and Aβ42. The latter one is regarded to be the more pathogenic amyloid peptide because of its strong tendency to form neurotoxic aggregates.
The β-secretase is a typical aspartyl protease. The γ-secretase is a proteolytic activity consisting of several proteins, its exact composition is incompletely understood. However, the presenilins are essential components of this activity and may represent a new group of atypical aspartyl proteases which cleave within the TM of their substrates and which are themselves polytopic membrane proteins. Other essential components of γ-secretase may be nicastrin and the products of the aph1 and pen-2 genes. Proven substrates for γ-secretase are the APP and the proteins of the Notch receptor family, however, γ-secretase has loose substrate specificity and may cleave further membrane proteins unrelated to APP and Notch.
The γ-secretase activity is absolutely required for the production of Aβ peptides. This has been shown both by genetic means, i.e., ablation of the presenilin genes and by low-molecular- weight inhibitory compounds. Since according to the amyloid hypothesis for AD the production and deposition of Aβ is the ultimate cause for the disease, it is thought that selective and potent inhibitors of γ-secretase will be useful for the prevention and treatment of AD.
An alternative mode of treatment is the modulation of the γ-secretase activity which results in a selective reduction of the Aβ42 production. This will result in an increase of shorter Aβ isoforms, such as Aβ38, Aβ37 or others, which have reduced capability for aggregation and plaque formation, and are less neurotoxic. Compounds which show this effect on modulating γ- secretase activity include certain non-steroidal anti-inflammatory drugs (NSAIDs) and related analogues (Weggen et al. Nature, 414 (2001) 212-16).
Thus, the compounds of this invention will be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer’s disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
Numerous documents describe the current knowledge on γ-secretase modulation, for example the following publications: Morihara et al, J. Neurochem., 83 (2002) 1009-12 Jantzen et al, J.Neuroscience, 22 (2002) 226-54 Takahashi et al, J. Biol. Chem., 278 (2003) 18644-70 Beher et al, J. Biol. Chem. 279 (2004) 43419-26 Lleo et al, Nature Med. 10 (2004) 1065-6 Kukar et al, Nature Med. 11 (2005) 545-50 Perretto et al, J. Med. Chem. 48 (2005) 5705-20 Clarke et al, J. Biol. Chem. 281 (2006) 31279-89 Stock et al, Bioorg. Med. Chem. Lett. 16 (2006) 2219–2223 Narlawar et al, J. Med. Chem. 49 (2006) 7588-91 The following definitions for compounds of formula I are used: As used herein, the term "lower alkyl" denotes a saturated straight- or branched-chain group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n- butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl groups are groups with 1 - 4 carbon atoms.
As used herein, the term "lower alkyl substituted by halogen" denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by halogen, for example CF , CHF , CH F, CH CF , CH CH CF , CF CHF , CH CF CF and the like. 2 2 2 3 2 2 3 2 2 2 2 3 As used herein, the term "lower alkyl substituted by hydroxy" denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by hydroxy, for example CH OH, CHCH OH or C(CH ) OH. 3 3 2 As used herein, the term "lower alkoxy" denotes an alkyl group as defined above, which is bonded via an O-atom.
The term "halogen" denotes chlorine, iodine, fluorine and bromine.
The term “a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N” is selected from the group consisting of N HN , , or The preferred five membered heteroaryl group is .
The term “a six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N” is selected from the group consisting of , , or . The preferred six membered heteroaryl groups are or .
The term “a two membered ring system containing 1 to 4 heteroatoms selected from S or N, wherein at least one ring is aromatic in nature” is selected from the group consisting of N N N S S N , , , , , , N N N N N N N or .
The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane- sulfonic acid, p-toluenesulfonic acid and the like.
Aspects of the present invention are compounds of formula I, the use of such compounds for the preparation of medicaments for the treatment of Alzheimer’s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi- infarct dementia, dementia pugilistica or Down syndrome, their manufacture and medicaments based on a compound of formula I in accordance with the invention.
Further embodiments of the invention are all forms of optically pure enantiomers, racemates or diastereomeric mixtures for compounds of formula I.
One aspect of the present invention are compounds of formula hetaryl II (R ) (R ) hetaryl I hetaryl I is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N; hetaryl II is a six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N, or is a two membered ring system containing 1 to 4 heteroatoms selected from S, or N, wherein at least one ring is aromatic in nature; R is lower alkyl, lower alkoxy, lower alkyl substituted by halogen, or halogen; R is lower alkyl, lower alkyl substituted by hydroxy or is –(CH ) -phenyl, optionally substituted by halogen; R is hydrogen or lower alkyl; Y is –(CH ) -, -CH OCH -, -CH O-, CH S-, -CH SCH - and is bonded to two of the 2 n 2 2 2 2 2 2 ring carbon atoms, bonding being to either the ring carbon atoms a and b or the ring carbon atoms c and d; p is 0 or 1; m is 0, 1 or 2; if m is 2 then R may be the same or different; n is 2 or 3; o is 0, 1 or 2, if o is 2, then R may be the same or different; or to pharmaceutically active acid addition salts thereof.
An embodiment of the invention are further compounds of formula I, hetaryl II (R ) (R ) hetaryl I wherein hetaryl I is pyridinyl, 1,2,4-thiadiazolyl, pyrazinyl or pyrimidinyl; hetaryl II is [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrazinyl, 5,6,7,8- tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-c]pyrimidinyl, 4,5,6,7-tetrahydro-benzothiazolyl or pyrimidinyl; R is methyl, chloro or CF : R is methyl, n-propyl, fluoro, chloro, trifluoromethyl, methoxy or is -C(CH ) OH, or is O-benzyl, or is cyclohexyl substituted by methyl or trifluoromethyl, or is furyl, or is –(CH ) -phenyl, optionally substituted by one, two or three halogen atoms selected from F or Cl, or by cyano or methoxy;; R is hydrogen or methyl; Y is –(CH ) -, or is – CH OCH -, or is – OCH -, or is – CH SCH -, or is – SCH and 2 n 2 2 2 2 2 2 is bonded to two of the ring carbon atoms, bonding being to either the ring carbon atoms a and b or the ring carbon atoms c and d; p is 0 or 1; m is 0, 1 or 2; n is 2, or 3; o is 1 or 2, if o is 2, then R may be the same or different; or pharmaceutically active acid addition salts thereof.
One embodiment of the invention are further compounds of formula I, wherein Y is –(CH ) -, hetaryl I is and hetaryl II is a two membered ring system containing 1 to 4 heteroatoms, for example the following compounds [(rac)exo(3-methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-(4-phenyl-4,5,6,7- tetrahydro-benzothiazolyl)-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(2-chloro fluoro-phenyl)methyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(2-chloro fluoro-phenyl)fluoro-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(4-chloro methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(3-cyano fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(3,4-difluoro- phenyl)trifluoromethly-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-methoxy- [1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-chloro trifluoromethyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[5,6-dimethyl- [1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-benzyloxy- [1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[5-propyl- [1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-(5-phenyl- [1,2,4]triazolo[1,5-a]pyrazinyl)-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[5- trifluoromethyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[6-chloro(3,4- difluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[7-methyl propyl-[1,2,4]triazolo[1,5-c]pyrimidinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(4,4- dimethyl-cyclohexyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-(7-furanyl- [1,2,4]triazolo[1,5-a]pyrimidinyl)-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[7- trifluoromethyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[ 8-(4- trifluoromethyl-cyclohexyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)(4-Fluoro-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl]-[(rac)exo (3-methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-amine or [(rac)(3,4-Difluoro-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl]-[(rac) endo(3-methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-amine.
A further embodiment of the invention are compounds of formula I for Y being –(CH ) -, hetaryl I is and hetaryl II is a six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N, for example the following compound 2-{6-(4-chloro-benzyl)[(rac)endo(3-methyl-[1,2,4]thiadiazolyl)aza- bicyclo[3.2.1]octylamino]-pyrimidinyl}-propanol A further embodiment of the invention are compounds of formula I for Y being –(CH ) -, hetaryl I is and hetaryl II is a two membered ring system containing 1 to 4 heteroatoms, for example the following compounds [(rac)exo(2-chloropyridinyl)aza-bicyclo[3.2.1]octyl]-[8-(3,4-difluorophenyl) methyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine or [8-(3,4-difluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-[(rac)endo(2-trifluoromethyl- pyridinyl)aza-bicyclo[3.2.1]octyl]-amine.
A further embodiment of the invention are compounds of formula I wherein heteroaryl I is and hetaryl II is a two membered ring system containing 1 to 4 heteroatoms, for example the following compounds [(rac)endo(6-methyl-pyrimidinyl)aza-bicyclo[3.2.1]octyl]-[8-(2,3,4-trifluoro- phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(6-Methyl-pyrimidinyl)oxaaza-bicyclo[3.2.1]octyl]-[8-(2,3,4- trifluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)exo(6-Methyl-pyrimidinyl)thiaaza-bicyclo[3.3.1]nonyl]-[8-(2,3,4- trifluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(6-Methyl-pyrimidinyl)aza-bicyclo[3.3.1]nonyl]-[8-(2,3,4-trifluoro- phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)exo(6-Methyl-pyrimidinyl)oxaaza-bicyclo[3.3.1]nonyl]-[8-(2,3,4- trifluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)exo-Methyl(6-methyl-pyrimidinyl)aza-bicyclo[3.2.1]octendo-yl]-[8-(2,3,4- trifluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine or [8-(3,4-Difluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-[(rac)endo(2-methyl- pyrimidinyl)aza-bicyclo[3.2.1]octyl]-amine.
The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which processes comprise a) reacting a compound of formula (R ) hetaryl I with a compound of formula (R ) hetaryl II to a compound of formula hetaryl II (R ) (R ) hetaryl I I wherein X is halogen and the further groups have the meaning as described above and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts; b) reacting a compound of formula hetaryl II (R ) with a compound of formula (R ) hetaryl I to a compound of formula hetaryl II (R ) (R ) hetaryl I wherein X is halogen and the further groups have the meaning as described above, or c) reacting a compound of formula (R ) hetaryl I with a compound of formula hetaryl II (R ) to a compound of formula hetaryl II (R ) (R ) hetaryl I wherein the groups have the meaning as described above and R is hydrogen, and, if desired converting the compounds obtained into pharmaceutically acceptable acid addition salts.
The preparation of compounds of formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the compounds of the invention are shown in the following schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein before unless indicated to the contrary.
In more detail, the compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. The reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity the sequence of reaction steps can be freely altered.
Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in the examples, or by methods known in the art.
Scheme 1 NH a hetaryl II (R ) (R ) hetaryl II m d (R ) hetaryl I (R ) hetaryl I The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by coupling of amines of general formula 2 and halides of general formula 3 (see Scheme 1).
This reaction can be accomplished using generally known procedures, e.g. displacement reactions under catalytic conditions (like e.g. palladium(0) or copper(II) catalysis) or under thermal conditions or under basic conditions.
Scheme 2 R R H NH X N hetaryl II hetaryl II (R ) PG (R ) PG 4 3 5 (R ) hetaryl I hetaryl II + 1 Y hetaryl II (R ) H (R ) (R ) hetaryl I Alternatively halides 3 can be coupled under conditions as described above with amines of general formula 4 which bear a protective group PG, e.g. Boc, on the piperidine nitrogen (see Scheme 2). After deprotection with e.g. trifluoro acetic acid, the piperidines 6 can be coupled with a hetaryl I halides of formula 7 to provide compounds of formula I.
Scheme 3 a H N Y hetaryl II hetaryl II (R ) (R ) (R ) (R ) hetaryl I hetaryl I hetaryl II hetaryl II Y (R ) PG PG (R ) 9 5 R is hydrogen; Alternatively anilines of general formula 9 can be employed in a reductive amination reaction with ketones of general formula 8 or 10 (see Scheme 3) providing compounds I either directly or after cleavage of protective group PG of 5, followed by coupling with heterorayl I halide 7 as described in Scheme 2. The reductive amination can be accomplished by methods known to one skilled in the art of organic synthesis, for example by heating the amine and the ketone in an appropriate solvent (e.g. toluene, dichloroethane, THF) possibly in the presence of an acid (e.g. acetic acid, tetraisopropyl-orthotitanate) and reduction of the intermediary imine with an appropriate reducing agent (e.g. sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, hydrogen in the presence paladium on charcoal).
Scheme 4 (R ) hetaryl I THF/Et N hetaryl II 3 hetaryl II c (R ) (R ) PG d N(H) hetaryl II 1 Y hetaryl II (R ) (R ) (R ) d (R ) hetaryl I hetaryl I reduction I N(H) N hetaryl II hetaryl II PG (R ) PG (R ) The coupling of anilines of general formula 9 with ketones of general formula 8 or 10 can alternatively be accomplished by following an aza-Wittig/reduction protocol (see Scheme 4).
Anilines of general formula 9 can be first converted to their corresponding trialkylphosphazenes 11 by reaction with trialkyldihalophosphorane (e.g. dichlorotrimethylphosphorane, prepared by reaction of trimethylphosphine with hexachloroethane in THF or dichloromethane) and an organic amine base (e.g. triethylamine, di-isopropylethylamine) in a suitable solvent (e.g. THF, dichloromethane). Ketones of general formula 8 or 10 are then added to the reaction mixture containing the in situ prepared phosphazenes 11 and the mixture is heated. The resulting imine/enamines (enamines maybe formed for compounds with a bridge Y between atoms a and b) 12 or 13 are then treated with an appropriate reducing agent (e.g. sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, decaborane, borane-THF complex, hydrogen in the presence palladium on charcoal) in the appropriate solvent (THF, DCM, MeOH and mixtures thereof) with or without acid catalysis (e.g. acetic acid) at ambient or elevated temperatures to provide compounds of general formula 5 or I (for R3 being hydrogen).
Scheme 5 H N N 2 thiophosgene, NH N base + Y Y PG d PG 14 15 16 MeI, DMA TMSONH N N N N PG PG 5a 17 A represents or .
Triazolopyridines of general formula 5a can alternatively be constructed by converting amines of general formula 14 into their corresponding isothiocyanates 15 (e.g. by reaction with thiosphosgene or 1,1’-thiocarbonyldiimidazole in dichloromethane in the presence of an organic or aqueous inorganic base) and reaction with amines of general formula 4 (see Scheme 5). The resulting thioureas 16 can be activated by alkylation with iodomethane and subsequently cyclised to triazolopyridines 5a by strong heating (> 130°C) in the presence of a suitably functionalised hydroxylamine derivative e.g. O-(trimethlysilyl)-hydroxylamine in a polar solvent e.g. dimethylacetamide.
Scheme 6 PG MeI, DMF b b N D 2 (R ) (R ) PG N NaN , DMF N D N H (R ) o b N D H (R ) H (R ) PG (R ) D represents a carbocyclic ring, preferrably Triazolopyridines of general formula 5b can be prepared by first condensing cyclic hydrazides 18 and isothiocyanates 19 (prepared by known methods to those skilled in the art) to form thiourea 20 (see Scheme 6). Activation of the sulphur group by alkylation (e.g. iodomethane in DMF at elevated temperatures) allows its displacement by an azide (e.g. sodium azide in DMF at elevated temperatures) to afford azidoguanidine 22. Staudinger reduction with trimethylphosphine generates an intermediate phosphazene 23 which cyclises on heating to generate triazolopyridine 5b.
Anilines of general formula 9, which can be used as starting materials for the preparation of compounds of formula I may be prepared as described in the following schemes.
Scheme 7 NH OH, H N H N N N 2 H N Pd, R -B(OH) 2 SCN-CO Et iPr EtN N N N 24 14 25 9a A represents or and X represents Cl or Br.
Anilines 9a in which heteroaryl II is an annelated triazole moiety (see Scheme 7) can be constructed from the corresponding amino derivatives 14, which are either commercially available or can be obtained from the corresponding halides 24 by palladium catalyzed Suzuki coupling with boronic acids or boronic esters (e.g. pinacol ester). Amines 14 can be reacted with ethoxycarbonyl isothiocyanate to yield thiourea derivatives 25 which undergo a cyclization reaction upon treatment with hydroxylamine in the presence of a base under liberation of carbon dioxide to yield annelated triazoles 9a (as e.g. described by M. Nettekoven et al., Synthesis 2003, 11, 1649-1652).
Scheme 8 e.g.
NH OH, H N N N Pd, R -B(OH) 2 H N N SCN-CO Et iPr EtN 2 or Cu(I), ArOH N N N N N N 24 26 27 9a A represents or and X represents Cl or Br.
Alternatively the order of steps in Scheme 7 can be changed (see Scheme 8). Halides 24 (which are either commercially available or can be synthesized by methods known in the art) can be reacted with ethoxycarbonyl isothiocyanate followed by treatment with hydroxylamine to provide annelated triazoles 27. These halides can then be subjected e.g. to palladium catalyzed Suzuki coupling with boronic acids or copper (I) catalyzed coupling with phenols (e.g. according to D. Maiti et al. JOC 2010, 75, 1791-1794) to provide substituted aminotriazoles 9a.
Scheme 9 H N H N H , Pd/C (R ) (R ) 9a 9b A is or , B is or , Compounds 9a can be hydrogenated with palladium on charcoal as catalyst to yield the corresponding partly saturated compounds 9b (see Scheme 9). Depending on the nature of ring A this reaction may require elevated temperature or hydrogen pressure or the presence of acid (e.g.
HCl). Alternatively compounds 9a can be reduced with metals e.g. magnesium in alcoholic solution (like ethanol) with or without activation of the metal (e.g. activation with catalytic amounts of iodine).
Scheme 10 (R ) (R ) C represents a carbocyclic ring, preferrably Anilines 9c in which heteroaryl II is a an annelated thiazole (see Scheme 10) can be prepared by condensation of -bromoketones 28 with thiourea (for example by heating in an appropriate solvent, e.g. ethanol). -Bromoketones are either commercially available or readily prepared by methods known to one skilled in the art of organic synthesis, e.g. by reaction of an appropriate ketone with bromine in chloroform.
Halides of general formula 3, which can be used as starting materials for the preparation of compounds of formula I may be prepared as described in the following schemes.
Scheme 11 (R ) (R ) H N X tBuONO N N N The halotriazole 3 can be prepared from the aniline 9 (see Scheme 11) via formation of the corresponding diazonium salt and subsequent decomposition in the presence of a halide source like copper (I) halide or hydrogenhalide (X = chlorine or bromine).
Scheme 12 Cl N Cl Cl N Cl Cl N R Cl N R 2''' 29 3a 2’ 2 2 R , R ’’ and R ’’’ is lower alkyl, lower alkyl substituted by hydroxy or is –(CH ) -phenyl, optionally substituted by halogen Halides 3a in which heteroaryl II is a pyrimidine (see Scheme 12) can be prepared as e.g. described in K. Baumann et al., WO2009103652 by reduction of trichloro-pyrimidines 29 to give dichloro-derivative 30, e.g. by treatment with zink in aquous ammonia at 0 C. Subsequently, the 4-chloro substituent of 30 can be replaced in a nucleophilic substitution reaction (like reaction with a Grignard reagent R MgX, e.g. benzylmagnesium chloride in tetrahydrofuran at -80 to +20 C) or, by a metal catalyst assisted displacement reaction (e.g. using palladium acetate, 2- (dicyclohexylphosphino-biphenyl, tetrahydrofuran, microwave oven, 30 min, 200 C).
Alternatively, one of the reactive chloro atoms of 29 is first replaced by a group R , followed by 2’’’ replacement of a second chloro-substituent in the intermediate 31 by a group R , to afford 3a.
Scheme 13 Cl N Cl Cl N Cl Cl N R MeO O OH R is –(CH ) -phenyl, optionally substituted by halogen Halides 3b in which heteroaryl II is a pyrimidine (see Scheme 13) can be prepared from 2,6- dichloro-pyrimidinecarboxylic acid methyl ester by reaction with e.g. methylmagnesium chloride in THF at -78°C to 0°C which provides 2-(2,6-dichloro-pyrimidinyl)-propanol.
The chloride in 4-position of 2-(2,6-dichloro-pyrimidinyl)-propanol can be replaced by a substituent R for example in a Suzuki coupling reaction with an aryl/ heteroaryl boronic acid/ ester R -B(OH/OR’) in the presence of a palladium catalyst and a base (e.g. sodium carbonate) in e.g. dimethoxyethane as solvent to provide chloride 3b. Alternatively the 4-chloro substituent can be reacted with an organo zinc chloride R ZnCl, e.g. benzylzinc chloride in the presence of a palladium catalyst to provide chloride 3b. To accomplish these modifications it might be necessary to protect the alcohol group of 2-(2,6-dichloro-pyrimidinyl)-propanol prior to the second step e.g. by protection with trimethylsilyl group which can be introduced e.g. with bis(trimethylsilyl)acetamide and can be cleaved after the modifications with e.g. p-TsOH in THF/water.
Ketones of general formula 8, which can be used as starting materials for the preparation of compounds of formula I may be prepared as described in the following schemes.
Scheme 14 10a 1 (R ) PG-NH hetaryl I O O O O HO OH Mannich reaction of the ketone in scheme 14 with formaldehyde and an appropriate amine PG- NH yields the ketone 10a. The protection group of 10a can be changed as appropriate (e.g. from benzyl to boc-protection). Condensation of 2,5-dimethoxy-tetrahydrofurane with the biacid in the presence of an appropriate amine PG-NH provides the ketone 10b. Deprotection of 10b or 10a and coupling with an appropriate hetaryl I halide under basic, thermal or metal catalyzed conditions yields the ketone 8.
Amines of general formula 2, which can be used as starting materials for the preparation of compounds of formula I may be prepared as described in the following schemes.
Scheme 15 (R ) (R ) hetaryl I hetaryl I HN O NH (R ) hetaryl I PG b The ketones 8 can be easily converted into the amines 2a (R = H) via reductive amination with ammonia, or hydroxyl amine or other suitable amine precursor (see Scheme 15). Preparation of amine 2b (R = Me) starts with the Grignard addition of a methyl grignard reagent to the ketone 10a. The resulting tertiary alcohol undergoes a Ritter reaction with acetonitrile under strong acidic conditions. Saponification of the amide and changing of the protection group to the hetaryl I group as previously described in scheme 14 yields the amine 2b.
Scheme 16 NHBoc NH NHBoc + N N Y S S d NHBoc NHBoc H N N N N N S b S Amines 2c in which heteroaryl I is a 3-methyl-[1,2,4]thiadiazole (see Scheme 15) can e.g. be prepared by palladium catalyzed coupling of 5-chloromethyl-[1,2,4]thiadiazole with piperidinyl-carbamic acid tert-butyl esters and subsequent cleavage of the Boc-protective group in the presence of an acid. Alternatively amines 2c can be prepared from the Boc- protected aminopiperidines by reaction with an isothiocyanate source like benzoylisothiocyanate, metal isothiocyanate, thiophosgen or an activated thiourea derivative to give the corresponding thiourea derivatives. Condensation with 1,1-dimethoxy-ethyl)-dimethyl-amine and subsequent cyclization with hydroxylamine-O-sufonic acid in the presence of a base like pyridine yields after deprotection the amines 2c.
Scheme 17 R H c hetaryl II hetaryl II (R ) (R ) (R ) (R ) hetaryl I o hetaryl I R is Cl R is OMe or OEt Compounds of general formula Ia where R is a halogen such as Cl can be converted into compounds of general formula Ib where R is alkoxy, such as OMe, OEt upon treatment with the appropriate sodium salt (NaOMe or NaOEt) in a suitable alcohol solvent such as methanol or ethanol respectively (see Scheme 17).
The compounds were investigated in accordance with the test given hereinafter.
Description of γ-secretase assay Cellular γ-secretase assay Human neuroglioma H4 cells overexpressing human APP were plated at 30,000 cells/well/200 µL in 96-well plates in IMDM media containing 10% FCS, 0.2 mg/L Hygromycin B and incubated for 2 hours at 37 °C, 5% CO prior to adding test compounds.
Compounds for testing were dissolved in 100% Me SO yielding in a 10 mM stock solution. Typically 12 µL of these solutions were further diluted in 1000 µL of IMDM media (w/o FCS). Subsequent 1:1 dilutions gave a ten point dose response curve. 100 µL of each dilution was added to the cells in 96-well plates. Appropriate controls using vehicle only and reference compound were applied to this assay. The final concentration of Me SO was 0.4%.
After incubation for 22 hours at 37 °C, 5% CO , 50 µL supernatant was transferred into round-bottom 96-well polypropylene plates for detection of Aβ42. 50 µL assay buffer (50 mM Tris/Cl, pH 7.4, 60 mM NaCl, 0.5% BSA, 1% TWEEN 20) was added to the wells followed by the addition of 100 µL of detection antibody (ruthenylated BAP15 0.0625 µg/mL in assay buffer). 50 µL of a premix of capture antibody (biotinylated 6E10 antibody, 1 µg/mL) and Steptavidin-coated magnetic beads (Dynal M-280, 0.125 mg/mL) were preincubated for 1 hour at room temperature before adding the assay plates. Assay plates were incubated on a shaker for 3 hours at room temperature and finally read in the Bioveris M8 Analyser according to the manufacturer’s instructions (Bioveris).
Toxicity of compounds was monitored by a cell viability test of the compound-treated cells using a colorimetric assay (CellTiter 96TM AQ assay, Promega) according to the manufacturer’s instructions. Briefly, after removal of 50 µL cell culture supernatant for detection of Aβ42, 20 µL of 1x MTS/PES solution was added to the cells and incubated for 30 minutes at 37 °C, 5% CO . Optical density was then recorded at 490 nm.
IC values for inhibition of Aβ42 secretion were calculated by nonlinear regression fit analysis using XLfit 4.0 software (IDBS).
In the list below are described the data for all compounds to the inhibition of Aβ42 secretion (µM): Example No. EC Aβ42 Example No. EC Aβ42 50 50 (µM) (µM) 1 2.95 15 0.217 2 0.41 16 0.235 3 3.37 17 0.273 4 0.627 18 0.158 0.273 19 0.42 6 0.179 20 0.289 7 0.175 21 0.553 8 0.199 22 0.623 9 0.232 23 0.917 0.296 24 0.300 11 0.428 25 3.237 12 0.833 26 3.833 13 0.557 27 0.643 14 0.215 28 0.642 The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.
The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an aspect of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
In accordance with the invention compounds of formula I as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses based on the inhibition of Aβ42 secretion, such as of Alzheimer’s disease.
The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
Tablet Formulation (Wet Granulation) Item Ingredients mg/tablet 25 100 500 1. Compound of formula I 5 25 100 500 2. Lactose Anhydrous DTG 125 105 30 150 3. Sta-Rx 1500 6 6 6 30 4. Microcrystalline Cellulose 30 30 30 150 . Magnesium Stearate 1 1 1 1 Total 167 167 167 831 Manufacturing Procedure 1. Mix items 1, 2, 3 and 4 and granulate with purified water. 2. Dry the granules at 50 °C. 3. Pass the granules through suitable milling equipment. 4. Add item 5 and mix for three minutes; compress on a suitable press.
Capsule Formulation Item Ingredients mg/capsule 25 100 500 1. Compound of formula I 5 25 100 500 2. Hydrous Lactose 159 123 148 --- 3. Corn Starch 25 35 40 70 4. Talc 10 15 10 25 . Magnesium Stearate 1 2 2 5 Total 200 200 300 600 Manufacturing Procedure 1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes. 2. Add items 4 and 5 and mix for 3 minutes. 3. Fill into a suitable capsule.
Example 1 [(rac)exo(2-Chloropyridinyl)aza-bicyclo[3.2.1]octyl]-[8-(3,4-difluorophenyl)- 6-methyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine Cl N a) 3-(3,4-Difluorophenyl)methylpyridinamine 3-Bromomethylpyridinamine (0.5 g, 2.7 mmol), 3,4-difluorophenylboronic acid (0.5 g, 3.2 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalldium(II)-dichloromethane complex (0.1 g, 0.1 mmol) were dissolved in a mixture of dioxane (10 mL) and 1M aqueous sodium carbonate solution (8 mL) under argon and the mixture was heated to 100 °C for 1 hour.
The reaction was diluted with ethyl acetate, separated and the organic layer was washed with brine, dried with sodium sulfate, filtered and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using n-heptane/ethyl acetate (v/v 1:1) as eluent. The title compound was obtained as a light brown crystalline solid (0.6 g, quant.).
MS ISP (m/e): 221.2 [(M+H) ].
H NMR (CDCl , 400 MHz): δ (ppm) = 7.95 (s, 1H), 7.32-7.16 (m, 4H), 4.50 (brs, 2H), 2.38 (s, 3H). b) 3-(3,4-Difluorophenyl)isothiocyanatomethylpyridine To a solution of 3-(3,4-difluorophenyl)methylpyridinamine (0.6g, 2.7 mmol) in dichloromethane (15 mL) was added a solution of sodium bicarbonate (2.3g, 26.7 mmol) in water (25 mL) followed by a solution of thiophosgene (0.25 mL, 3.2 mmol) in dichloromethane (1 mL) and the mixure stirred for 15 minutes. The phases were separated and the organic phase was dried with sodium sulfate and the solvent was evaporated in vacuo to afford the title compound was obtained as a crystalline yellow solid (0.7 g, 100 %).
MS ISP (m/e): 263.2 [(M+H) ].
H NMR (CDCl , 400 MHz): δ (ppm) = 8.27 (s, 1H), 7.50 (s, 1H), 7.32-7.25 (m, 2H), 7.22-7.18 (m, 1H), 2.39 (s, 3H). c) 1-((rac)exoBenzylazabicyclo[3.2.1]octanyl)(3-(3,4-difluorophenyl) methylpyridinyl)thiourea To a solution of 3-(3,4-difluorophenyl)isothiocyanatomethylpyridine (0.3 g, 1.1 mmol) in dimethylacetamide (0.2 mL) was added (rac)exobenzylazabicyclo[3.2.1]octanamine (0.3 g, 1.1 mmol) and the mixture was heated to 50 °C for 15 minutes. The reaction was diluted with ethyl acetate, washed with water, brine, dried with sodium sulfate and the solvent was partially evaporated under reduced pressure resulting in the product crystallising. The title compound was obtained as an off-white crystalline solid (0.4 g, 75 %).
MS ISP (m/e): 479.3 [(M+H) ].
H NMR (CDCl , 400 MHz): δ (ppm) = 12.57 (brs, 1H), 12.24 (d, 1H), 8.21 (s, 1H), 7.89-7.82 (m, 3H), 7.47-7.44 (m, 3H), 7.35-7.30 (m, 2H), 7.21-7.16 (m, 1H), 7.13-7.09 (m, 1H), 4.97-4.86 (m, 1H), 4.10 (d, 2H), 3.80 (s, 2H), 2.93 (t, 2H), 2.35-2.17 (m, 8H). d) Methyl N'-((rac)exobenzylazabicyclo[3.2.1]octanyl)-N-(3-(3,4-difluorophenyl) methylpyridinyl)carbamimidothioate To a solution of 1-((rac)exobenzylazabicyclo[3.2.1]octanyl)(3-(3,4- difluorophenyl)methylpyridinyl)thiourea (0.3 g, 0.6 mmol) in dimethylacetamide (1.5 mL) was added iodomethane (0.06 mL, 1.0 mmol) and the mixture was heated to 80 °C for 2 hours.
The reaction was evaporated to dryness, the residue redisolved in ethyl acetate, washed with saturated sodium hydrogen carbonate, brine, dried with sodium sulfate, filtered and the solvent evpaorated under reduced pressure. The title compound was obtained as a light yellow gum (0.3 g, 94 %).
MS ISP (m/e): 493.2 [(M+H) ]. e) ((rac)exoBenzylazabicyclo[3.2.1]octanyl)(3,4-difluorophenyl)methyl- [1,2,4]triazolo[1,5-a]pyridinamine To a solution of methyl N'-((rac)exobenzylazabicyclo[3.2.1]octanyl)-N-(3-(3,4- difluorophenyl)methylpyridinyl)carbamimidothioate (0.05 g, 0.1 mmol) in DMF (0.5 mL) was added O-(trimethylsilyl)-hydroxylamine (0.03 mL, 0.2 mmol) and the mixture heated to 150 °C for 1 hour followed by 1 hour at 200 °C in the microwave. The reaction was diluted with ethyl acetate, washed with water, brine, dried with sodium sulfate, filtered and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using n-heptane/ethyl acetate (v/v 1:1 to 0:1) as eluent. The title compound was obtained as a light brown gum (0.01 g, 22 %).
MS ISP (m/e): 460.2 [(M+H) ].
H NMR (CDCl , 400 MHz): δ (ppm) = 8.10 (s, 1H), 7.94-7.90 (m, 1H), 7.40-7.16 (m, 1H), 4.93-4.82 (m, 7H), 4.39 (s, 1H), 4.30 (d, 1H), 4.07-3.95 (m, 1H), 3.60 (s, 2H), 3.27 (s, 2H), 2.38 (s, 3H) 2.11-1.99 (m, 4H), 1.83-1.72 (m, 2H), 1.62 (t, 2H). f) ((rac)exo(2-Chloropyridinyl)azabicyclo[3.2.1]octanyl)(3,4-difluorophenyl)- 6-methyl-[1,2,4]triazolo[1,5-a]pyridinamine To a solution of ((rac)exobenzylazabicyclo[3.2.1]octanyl)(3,4-difluorophenyl) methyl-[1,2,4]triazolo[1,5-a]pyridinamine (0.02 g, 0.03 mmol) in methanol (1 mL) was added a spatula tip of 10% palladium on charcoal, followed by a drop of 25 % aqueous hydrogen chloride solution and the mixture stirred under an atmosphere of hydrogen (balloon) for 3 hours.
The reaction was filtered through Hyflo and concentrated to dryness. The residue was redissolved in dimethylacetamide (1 mL), the mixture made basic by addition of triethylamine and 2-chlorofluoropyridine (0.02 g, 0.15 mmol) was added. The mixture was heated to 120°C for 3 hours after which time it was diluted with ethyl acetate, washed with water, brine, dried with sodium sulfate, filtered and the solvent evpaorated under reduced pressure. The residue was purified by column chromatography on silica gel using n-heptane/ethyl acetate (v/v 7:3 to 1:7) as eluent. The title compound was obtained as an off-white solid (0.05 g, 33 %).
MS ISP (m/e): 481.2 [(M+H) ].
H NMR (CDCl , 400 MHz): δ (ppm) = 8.11 (s, 1H), 8.00 (d, 1H), 7.97-7.91 (m, 1H), 7.71-7.67 (m, 1H), 7.34 (s, 1H), 7.23-7.16 (m, 1H), 6.57 (d, 1H), 6.48 (dd, 1H), 4.37-4.26 (m, 3H), 2.18- 2.11 (m, 4H), 2.05-2.00 (m, 2H), 1.61 (t, 2H).
Example 2 [(rac)exo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-(4-phenyl- 4,5,6,7-tetrahydro-benzothiazolyl)-amine a) 3-(4-Phenyl-4,5,6,7-tetrahydro-benzothiazolylamino)-(rac)exoaza- bicyclo[3.2.1]octanecarboxylic acid tert-butyl ester To a solution of 4-phenyl-4,5,6,7-tetrahydro-benzothiazolylamine (46 mg, 0.2 mmol) in dichloroethane (0.6 mL) was added at room temperature under stirring BOC-nortropinone (64 mg, 0.28 mmol) and tetraisopropyl-orthotitanat (178 µL, 0.6 mmol). The reaction was stirred over night at 90 °C in a sealed tube under nitrogen. At room temperature ethanol (0.6 mL) and sodium borohydride (15 mg, 0.4 mmol) were added and the reaction was stirred at 85 °C for 4 hours and 30 minutes. Water was added, the reaction was stirred for 30 minutes and the precipitate was filtered off and washed with ethanol. The filtrate was concentrated under reduced pressure. Water was added and the reaction was extracted twice with ethyl acetate. The combined organic layers were washed with concentrated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a gradient from CH Cl to CH Cl /MeOH 19:1 2 2 2 2 (v/v) as eluent to yield the title compound as a light brown solid (73 mg, 83 %).
MS ISP (m/e): 440.3 (100) [(M+H) ]. b) ((rac)exoAza-bicyclo[3.2.1]octyl)-(4-phenyl- 4,5,6,7- tetrahydro - benzothiazol yl)-amine hydrochloride To a solution of 3-(4-phenyl-4,5,6,7-tetrahydro-benzothiazolylamino)-(rac)exoaza- bicyclo[3.2.1]octanecarboxylic acid tert-butyl ester (93 mg, 0.21 mmol) in methylene chloride (5 mL) was added 2 M hydrogen chloride solution in diethyl ether (1.1 mL). The reaction was stirred at room temperature overnight. The solvent was removed under reduced pressure and the residue was treated with diethyl ether and evaporated. The title compound was obtained as a light brown solid (76 mg, 96 %).
MS ISP (m/e): 340.2 (100) [(M+H) ], 231.2 (34). c) [(rac)exo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-(4-phenyl- 4,5,6,7-tetrahydro-benzothiazolyl)-amine Palladium (II) acetate (3.3 mg, 0.015 mmol) and 2-(dicyclohexylphosphino)biphenyl (11 mg, 0.03 mmol) were stirred under nitrogen at room temperature in dioxane (1.7 mL) for 10 minutes.
Sodium tert.-butylat (27 mg, 0.28 mmol), ((rac)exoaza-bicyclo[3.2.1]octyl)-(4-phenyl- 4,5,6,7- tetrahydro - benzothiazolyl)-amine hydrochloride (70 mg, 0.19 mmol), N,N- diisopropylethylamine (63 µL, 0.37 mmol) and 5-chloromethyl-[1,2,4]thiadiazole (28 mg; 0.21 mmol) were added and the reaction was heated to 200 °C for 30 minutes in a microwave oven. The reaction was diluted with water and extracted twice with ethyl acetate. The combined organic layers were washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a gradient from CH Cl to CH Cl /MeOH 19:1 (v/v) as eluent. The title compound was obtained 2 2 2 2 as a light yellow solid (48 mg, 59 %).
MS ISP (m/e): 438.2 (100) [(M+H) ].
H NMR (CDCl , 300 MHz): δ (ppm) = 7.28 (d, 1H), 7.18 (t, 2H), 7.11 (t, 1H), 4.70 (m, 0.5H), 4.51 (m, 0.5H), 4.21 (m, 1.5H), 4.00 (m, 1H), 3.60 (m, 0.5H), 2.72 (m, 2H), 2.47 (s, 1.5H), 2.42 (s, 1.5H), 2.32 (m, 1H), 2.15 (m, 3H), 2.18 (m, 5H), 1.65 (m, 3H).
Example 3 2-{6-(4-Chloro-benzyl)[(rac)endo(3-methyl-[1,2,4]thiadiazolyl)aza- bicyclo[3.2.1]octylamino]-pyrimidinyl}-propanol N HN N a) (rac)[(Z)-Hydroxyimino]aza-bicyclo[3.2.1]octanecarboxylic acid tert-butyl ester To a solution of Boc-nortropinone (1.13 g, 5 mmol) in ethanol (5 mL) was added under stirring hydroxylamine hydrochloride (0.695 g, 10 mmol) in water (5 mL). Sodium bicarbonate (0.84 g, mmol) was added portion wise and the reaction was refluxed for 45 minutes under nitrogen and stirred at room temperature overnight. The solvent was evaporated under reduced pressure.
Water was added and the reaction was extracted twice with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure to yield the title compound as a brown oil (1.28 g, 100 %). b) (rac)endoAminoaza-bicyclo[3.2.1]octanecarboxylic acid tert-butyl ester A solution of (rac)[(Z)-hydroxyimino]aza-bicyclo[3.2.1]octanecarboxylic acid tert-butyl ester (635 mg, 2.64 mmol) in ethanol (4 mL) and acetic acid (1 mL) was hydrogenated under an atmosphere of hydrogen over night at room temperature in the presence of PtO (42 mg, 6.6 weight %). Another portion of PtO (42 mg) was added and the reaction was further hydrogenated overnight. The catalyst was filtered off, washed with ethanol. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel using CH Cl /MeOH/NH 19:1:0.1 (v/v/v) as eluent to yield the title compound as a 2 2 3 yellow solid (622 mg, 100 %).
MS ISP (m/e): 227.3 (100) [(M+H) ]. c) (rac)-(3-endo)[4-(4-Chloro-benzyl)(1-hydroxymethyl-ethyl)-pyrimidinylamino] aza-bicyclo[3.2.1]octanecarboxylic acid tert-butyl ester A solution of (rac)endoaminoaza-bicyclo[3.2.1]octanecarboxylic acid tert-butyl ester (189 mg, 0.837 mmol), 2-[2-chloro(4-chloro-benzyl)-pyrimidinyl]-propanol (342 mg, 0.92 mmol) and N,N-diisopropylethyl amine (214 µL, 1.26 mmol) in dioxane (2 mL) was heated at 150 °C in a microwave oven for 1 hour. The reaction was diluted with water and extracted twice with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a gradient from CH Cl to CH Cl :MeOH 19:1 (v/v) as eluent. The title compound was obtained as a yellow oil 2 2 2 2 (86 mg, 21 %).
MS ISP (m/e): 487.4 (100) [(M+H) ]. d) 2-[2-[(rac)-(3-endo)-(8-Aza-bicyclo[3.2.1]octyl)amino] (4-chloro-benzyl)-pyrimidin yl]-propanol hydrochloride To a solution of (rac)endo[4-(4-chloro-benzyl)(1-hydroxymethyl-ethyl)-pyrimidin ylamino]aza-bicyclo[3.2.1]octanecarboxylic acid tert-butyl ester (86 mg, 0.177 mmol) in methylene chloride (2 mL) was added at room temperature under stirring a 2 M hydrogen chloride solution in diethyl ether (0.9 mL) and was stirred at room temperature overnight. The solvent was removed under reduced pressure and trifluoroacetic acid (2 mL) was added. The solvent was removed under reduced pressure to yield the title compound as a brown gum (95 mg, 127 %) MS ISP (m/e): 387.4 (100) [(M+H) ]. e) 2-{6-(4-Chloro-benzyl)[(rac)endo(3-methyl-[1,2,4]thiadiazolyl)aza- bicyclo[3.2.1]octylamino]-pyrimidinyl}-propanol Palladium (II) acetate (3.8 mg, 0.017 mmol) and 2-(dicyclohexylphosphino)biphenyl (12 mg, 0.034 mmol) were stirred under nitrogen at room temperature in dioxane (1 mL) for 10 minutes.
Sodium tert.-butylat (32 mg, 0.32 mmol), 2-[2-[(rac)endo-(8-aza-bicyclo[3.2.1]oct yl)amino] (4-chloro-benzyl)-pyrimidinyl]-propanol hydrochloride (90mg, 0.213 mmol), N,N-diisopropylethylamine (72.3 µl, 0.425 mmol) in dioxane (2 mL) and 5-chloromethyl- [1,2,4]-thiadiazole (32 mg; 0.234 mmol) were added and the reaction was heated to 150 °C for 1 hour in a microwave oven. The reaction was diluted with water and extracted twice with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a gradient from CH Cl to CH Cl :MeOH 19:1 (v/v) as eluent. The title compound was obtained as a light brown gum (55 mg, 48 %).
MS ISP (m/e): 485.4/487.4 (100/33) [(M+H) ], 467.3/469.3 (38/16).
H NMR (CDCl , 300 MHz): δ (ppm) = 7.28 (d, 2H), 7.19 (d, 2H), 6.43 (s, 1H), 4.94 (br d, 1H), 4.22 (m, 2H), 4.19 (m, 1H), 3.85 (s, 2H), 3.70 (s, 1H), 2.45 (m, 2H), 2.44 (s, 3H), 2.19 (m, 4H), 1.92 (d, 2H), 1.41 (s, 6H).
Example 4 [8-(3,4-Difluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-[(rac)endo(2- trifluoromethyl-pyridinyl)aza-bicyclo[3.2.1]octyl]-amine a) (rac)endoBenzylazabicyclo[3.2.1]octanamine (rac)Benzylazabicyclo[3.2.1]octanone oxime (1.2 g, 5.1 mmol, WO2005/21536 A2) was dissolved in methanol (20 mL), a generous spatula of Raney nickel was added and the mixture stirred under an atmosphere of hydrogen for 1 hour after which time it was filtered through Hyflo and concentrated. The residue was purified by column chromatography on silica gel using a gradient from CH Cl :MeOH (v/v 9:1-7:3) as eluent. The title compound was obtained as a waxy solid (0.3 g, 26 %) as well as the earlier eluting exo-isomer (0.4 g, 36 %).
MS ISP (m/e): 217.2 [(M+H) ].
H NMR (CDCl , 400 MHz): δ (ppm) = 7.32-7.21 (m, 5H), 3.46 (s, 2H), 2.88 (s, 1H), 2.67 (dd, 2H), 2.11 (d, 2H), 1.97 (brs, 2H), 1.81-1.74 (m, 4H). b) N-(3-Bromo-pyridinyl)-N’-ethoxycarbonyl-thiourea 3-Bromopyridinamine (30 g, 168 mmol) and ethoxycarbonyl isothiocyanate (24.8 g, 21.3 mL, 185 mmol) were dissolved in dioxane (300 mL) and stirred at room temperature. After 4 hours further ethoxycarbonyl isothiocyanate (1 mL, 8.4 mmol) was added. After 1 hour the solvent was evaporated and the residue dried in high vacuum for 12 hours. The title compound was obtained as a light yellow solid (51.2 g, 100 %) and was used crude for the next step.
MS ISP (m/e): 304.0/ 305.9 (100/ 73) [(M+H) ].
H NMR (CDCl , 300 MHz): δ

Claims (19)

Claims
1. A compound of formula hetaryl II (R ) (R ) hetaryl I hetaryl I is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N; 10 hetaryl II is a six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N, or is a two membered ring system containing 1 to 4 heteroatoms selected from S, or N, wherein at least one ring is aromatic in nature; R is lower alkyl, lower alkoxy, lower alkyl substituted by halogen or halogen; R is lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, cycloalkyl substituted by lower alkyl or lower alkyl substituted by halogen, or is lower alkyl substituted by hydroxy, furyl, O-benzyl, or –(CH ) -phenyl, optionally substituted by halogen, lower alkoxy, lower alkyl substituted by 20 halogen, lower alkyl or by cyano; R is hydrogen or lower alkyl; Y is –(CH ) -, -CH OCH -, -CH O-, CH S-, -CH SCH - and is bonded to two of the 2 n 2 2 2 2 2 2 25 ring carbon atoms, bonding being to either the ring carbon atoms a and b or the ring carbon atoms c and d; p is 0 or 1; m is 0, 1 or 2; if m is 2 then R may be the same or different; n is 2 or 3; o is 0, 1 or 2, if o is 2, then R may be the same or different; or a pharmaceutically active acid addition salts thereof.
2. A compound of formula I according to claim 1, hetaryl II (R ) (R ) hetaryl I wherein hetaryl I is pyridinyl, 1,2,4-thiadiazolyl, pyrazinyl or pyrimidinyl; 10 hetaryl II is [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrazinyl, 5,6,7,8- tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-c]pyrimidinyl, 4,5,6,7-tetrahydro-benzothiazolyl or pyrimidinyl; R is methyl, chloro or CF : R is methyl, n-propyl, fluoro, chloro, trifluoromethyl, methoxy or is -C(CH ) OH, 15 or is O-benzyl, or is cyclohexyl substituted by methyl or trifluoromethyl, or is furyl, or is –(CH ) -phenyl, optionally substituted by one, two or three halogen atoms selected from F or Cl, or by cyano or methoxy;; R is hydrogen or methyl; Y is –(CH ) -, or is – CH OCH -, or is – OCH -, or is – CH SCH -, or is – SCH and 2 n 2 2 2 2 2 2 20 is bonded to two of the ring carbon atoms, bonding being to either the ring carbon atoms a and b or the ring carbon atoms c and d; p is 0 or 1; m is 0, 1 or 2; n is 2, or 3; 25 o is 1 or 2, if o is 2, then R may be the same or different; or pharmaceutically active acid addition salts thereof.
3. A compound of formula I according to any one of claims 1 or 2, wherein Y is –(CH ) -, hetaryl I is and hetaryl II is a two membered ring system containing 1 to 4 heteroatoms. 5
4. A compound of formula I according to any one of claims 1 to 3, wherein the compounds are [(rac)exo(3-methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-(4-phenyl-4,5,6,7- tetrahydro-benzothiazolyl)-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(2-chloro 10 fluoro-phenyl)methyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(2-chloro fluoro-phenyl)fluoro-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(4-chloro methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine 15 [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(3-cyano fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(3,4-difluoro- phenyl)trifluoromethly-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-methoxy- 20 [1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-chloro trifluoromethyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[5,6-dimethyl- [1,2,4]triazolo[1,5-a]pyridinyl]-amine 25 [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-benzyloxy- [1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[5-propyl- [1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-(5-phenyl- 30 [1,2,4]triazolo[1,5-a]pyrazinyl)-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[5- trifluoromethyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[6-chloro(3,4- difluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[7-methyl propyl-[1,2,4]triazolo[1,5-c]pyrimidinyl]-amine 5 [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[8-(4,4- dimethyl-cyclohexyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-(7-furanyl- [1,2,4]triazolo[1,5-a]pyrimidinyl)-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[7- 10 trifluoromethyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(3-Methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-[ 8-(4- trifluoromethyl-cyclohexyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)(4-Fluoro-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl]-[(rac)exo (3-methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-amine or 15 [(rac)(3,4-Difluoro-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl]-[(rac) endo(3-methyl-[1,2,4]thiadiazolyl)aza-bicyclo[3.2.1]octyl]-amine.
5. A compound of formula I according to any one of claims 1 or 2, wherein Y is –(CH ) -, hetaryl I is and hetaryl II is a six membered heteroaryl group, containing 1 20 to 3 heteroatoms, selected from S or N.
6 A compound of formula I according to any one of claims 1, 2 or 5, wherein the compound is 2-{6-(4-chloro-benzyl)[(rac)endo(3-methyl-[1,2,4]thiadiazolyl)aza- 25 bicyclo[3.2.1]octylamino]-pyrimidinyl}-propanol.
7. A compound of formula I according to any one of claims 1 or 2, wherein Y is –(CH ) -, hetaryl I is and hetaryl II is a two membered ring system containing 1 to 4 heteroatoms.
8. A compound of formula I according to any one of claims 1, 2 or 7, wherein the compounds are [(rac)exo(2-chloropyridinyl)aza-bicyclo[3.2.1]octyl]-[8-(3,4-difluorophenyl) methyl-[1,2,4]triazolo[1,5-a]pyridinyl]-amine or 5 [8-(3,4-difluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-[(rac)endo(2-trifluoromethyl- pyridinyl)aza-bicyclo[3.2.1]octyl]-amine.
9. A compound of formula I according to any one of claims 1 or 2, wherein heteroaryl I is and hetaryl II is a two membered ring system containing 1 to 4 heteroatoms and 10 the other definitions are as described in claim 1.
10. A compound of formula I according to any one of claims 1, 2 or 9, wherein the compounds are [(rac)endo(6-methyl-pyrimidinyl)aza-bicyclo[3.2.1]octyl]-[8-(2,3,4-trifluoro- 15 phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)endo(6-Methyl-pyrimidinyl)oxaaza-bicyclo[3.2.1]octyl]-[8-(2,3,4- trifluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)exo(6-Methyl-pyrimidinyl)thiaaza-bicyclo[3.3.1]nonyl]-[8-(2,3,4- trifluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine 20 [(rac)endo(6-Methyl-pyrimidinyl)aza-bicyclo[3.3.1]nonyl]-[8-(2,3,4-trifluoro- phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)exo(6-Methyl-pyrimidinyl)oxaaza-bicyclo[3.3.1]nonyl]-[8-(2,3,4- trifluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine [(rac)exo-Methyl(6-methyl-pyrimidinyl)aza-bicyclo[3.2.1]octendo-yl]-[8-(2,3,4- 25 trifluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-amine or [8-(3,4-Difluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridinyl]-[(rac)endo(2-methyl- pyrimidinyl)aza-bicyclo[3.2.1]octyl]-amine. 30
11. A process for preparing a compound of formula I as defined in any one of claims 1 - 10, which process comprises a) reacting a compound of formula (R ) hetaryl I with a compound of formula (R ) hetaryl II to a compound of formula hetaryl II (R ) (R ) hetaryl I 5 I wherein X is halogen and the further groups have the meaning as described above and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts; 10 b) reacting a compound of formula hetaryl II (R ) with a compound of formula (R ) hetaryl I 15 to a compound of formula hetaryl II (R ) (R ) hetaryl I wherein X is halogen and the further groups have the meaning as described above, or c) reacting a compound of formula (R ) hetaryl I 5 with a compound of formula hetaryl II (R ) to a compound of formula hetaryl II (R ) (R ) hetaryl I wherein the groups have the meaning as described above and R is hydrogen, and, if desired converting the compounds obtained into pharmaceutically acceptable acid addition salts.
12. A compound according to any one of claims 1 - 10, whenever prepared by a process 15 as claimed in claim11.
13. A medicament containing one or more compounds as claimed in any one of claims 1 – 10 and pharmaceutically acceptable excipients. 20
14. A medicament according to claim 13 for the treatment of Alzheimer’s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
15. The use of a compound in any one of claims 1 - 10 for the manufacture of 25 medicaments for the treatment of Alzheimer’s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
16. A compound according to any one of claims 1 – 10 for use as therapeutically active 5 substance.
17. A compound according to any one of claims 1 – 10 for the treatment of Alzheimer’s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch- type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
18. A medicament according to claim 13 substantially as herein described with reference to any example thereof.
19. A process according to claim 11 for preparing a compound of formula I substantially 15 as herein described with reference to any example thereof.
NZ612525A 2011-03-02 2012-02-28 Bridged piperidine derivatives NZ612525B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11156587 2011-03-02
EP11156587.5 2011-03-02
PCT/EP2012/053301 WO2012116965A1 (en) 2011-03-02 2012-02-28 Bridged piperidine derivatives

Publications (2)

Publication Number Publication Date
NZ612525A NZ612525A (en) 2015-08-28
NZ612525B2 true NZ612525B2 (en) 2015-12-01

Family

ID=

Similar Documents

Publication Publication Date Title
EP2681214B1 (en) Bridged piperidine derivatives
RU2686117C1 (en) Condensed derivatives of imidazole and pyrazole as modulators of activity tnf
JP5559362B2 (en) Piperidine derivatives
US10604517B2 (en) Bridged piperidine derivatives
US10562903B2 (en) Bridged piperidine derivatives
EP3519418B1 (en) Bridged piperidine derivatives
EP3535266B1 (en) Bicyclic heteroaryl derivatives
US10875854B2 (en) Triazolopyridines
NZ612525B2 (en) Bridged piperidine derivatives
EP3863713B1 (en) Phenyltetrazole derivatives as plasma kallikrein inhibitors
AU2012222426B2 (en) Bridged piperidine derivatives
CA3237119A1 (en) Compound having btk protein degradation activity, and medical uses thereof